Application of combination of berberine and formononetin in preparation of anti-tumor medicines

A technology of formononetin and antineoplastic drugs, applied in the field of medicine

Pending Publication Date: 2019-12-20
HUNAN UNIV OF CHINESE MEDICINE
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There is no report that berberine combined with formononetin has anti-tumor synergistic effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of combination of berberine and formononetin in preparation of anti-tumor medicines
  • Application of combination of berberine and formononetin in preparation of anti-tumor medicines
  • Application of combination of berberine and formononetin in preparation of anti-tumor medicines

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] Example 1: Synergistic effect experiment of berberine combined with formononetin in inhibiting the proliferation of nasopharyngeal carcinoma cells

[0043] 1. Inhibitory effect of berberine alone on nasopharyngeal carcinoma cells

[0044] Treating CNE2 nasopharyngeal carcinoma cells with berberine (Ber) alone can significantly inhibit the proliferation of nasopharyngeal carcinoma cells at 24 hours, 36 hours, 48 ​​hours, and 72 hours. The inhibition rates are shown in Table 1.

[0045] Table 1 The inhibitory effect of berberine on the proliferation of nasopharyngeal carcinoma cells ( %, n=3)

[0046]

[0047] 2. The inhibitory effect of formononetin alone on nasopharyngeal carcinoma cells

[0048] Treating CNE2 nasopharyngeal carcinoma cells with formononetin (Form) alone can significantly inhibit the proliferation of nasopharyngeal carcinoma cells at 24 hours, 36 hours, 48 ​​hours, and 72 hours. The inhibition rates are shown in Table 2.

[0049] Table 2 The inhi...

Embodiment 2

[0057] Example 2: Berberine combined with formononetin has a synergistic effect in inducing apoptosis of nasopharyngeal carcinoma cells

[0058] According to the result of embodiment 1, adopt factorial design, select 0, 5 μ M, 10 μ M different concentrations of berberine (Ber) and 0, 5 μ M, 10 μ M different concentrations of formononetin (Form) to be divided into 9 groups: 0 ( control, solvent control group), Ber 5, Ber10, Form 5, Form10, (Ber 5+Form 5), (Ber 5+Form 10), (Ber 10+Form 5), (Ber 10+Form10), another setting Positive control cisplatin group (concentration is 4.0 μg.mL -1 ). To observe the effect of the combination of two drugs on the apoptosis of nasopharyngeal carcinoma cells.

[0059] 1. Flow cytometry detection of the effect of berberine combined with formononetin on the apoptosis of nasopharyngeal carcinoma cells

[0060] Flow cytometry was used to further detect the effect of drugs on the apoptosis of nasopharyngeal carcinoma cells. 0, 5 μM, 10 μM berberin...

Embodiment 3

[0065] Example 3: Berberine combined with formononetin has a synergistic effect on inhibiting the migration of nasopharyngeal carcinoma cells

[0066] 1. Scratch test to observe the effect of berberine combined with formononetin on the migration of nasopharyngeal carcinoma cells

[0067] 0, 5 μM, 10 μM berberine and 0, 5 μM, 10 μM formononetin were used respectively, and the effect on the migration of nasopharyngeal carcinoma cells was observed by scratch test, and the combined drug index was calculated. According to the analysis method of drug compatibility effect, combination index CI>1 is an antagonistic effect, CI=1 is an additive effect, and CI Figure 4 and Table 4. According to the migration inhibition rate, each drug group can significantly inhibit the migration of nasopharyngeal carcinoma cells, and (Ber 5+Form 5), (Ber 5+Form 10), (Ber 10+Form 5), (Ber 10+Form 10) groups The migration inhibition rate was significantly higher than that of the single drug group, and th...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of a combination of berberine and formononetin in the preparation of anti-tumor medicines, specifically in treatment of nasopharyngeal carcinoma. The combinationof the two medicines has an unexpected synergistic effect, has no toxic or side effect and has great application value in the treatment of nasopharyngeal carcinoma.

Description

technical field [0001] The invention belongs to the field of medicine, in particular relates to berberine and formononetin as drugs for treating tumors and their application, and more specifically relates to drugs for treating nasopharyngeal carcinoma. Background technique [0002] Nasopharyngeal carcinoma (Nasopharyngeal carcinoma, NPC) is a malignant tumor of epithelial origin. About 80% of nasopharyngeal carcinoma occurs in my country, accounting for the first place in head and neck tumors in my country. Its pathogenesis is not yet fully understood, and it is believed that its occurrence is closely related to genetic factors, microbial infections (EB virus, etc.), environment, diet and social factors. The diagnosis of nasopharyngeal carcinoma mainly relies on routine imaging examination and pathological examination, lacking reliable early diagnosis indicators and means. Therefore, when patients come to see a doctor, 70%-80% of the patients already have cervical lymph nod...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4375A61K31/352A61P35/00A61P35/04
CPCA61K31/4375A61K31/352A61P35/00A61P35/04
Inventor 何迎春胡晶何兰戴娜周芳亮蔺婷范婧莹
Owner HUNAN UNIV OF CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap